Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition

Recruitment & Eligibility

Inclusion Criteria

Healthy human subjects aged between 18 and 45 years (including both).
Subjects with a BMI between 18.5 - 24.9 Kg/m2 (including both) but body weight not less than 45 Kgs.
Subjects with normal health as determined by personal medical history, clinical examination, and laboratory examinations including serological tests.
Subjects having normal 12-lead electrocardiogram (ECG).
Subjects having normal chest X-Ray (PIA view).
Subjects able to communicate effectively.
Subjects willing to give written informed consent and adhere to all the requirements of this protocol.
Female subjects who are postmenopausal or surgically sterile.
Female subjects practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm,intrauterine device (IUD) or abstinence.

Exclusion Criteria

Subjects having contraindications or hypersensitivity to ropinirole or domperidone or related group of drugs.
History or presence of any medical condition or disease according to the opinion of the physician.
History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
History or presence of significant alcoholism or drug abuse in the past one year.
History or presence of significant smoking (more than 10 cigarettes or bidis/day or consumption of tobacco products).
Difficulty with donating blood.
Difficulty in swallowing solids like tablets or capsules.
Systolic blood pressure less than 110mm Hg or more than 140 mm Hg.
Diastolic blood pressure less than 70 mm Hg or more than 90 mm Hg.
Pulse rate less than 50 beats/minute or more than 100 beats/minute.
Use of any prescribed medication during last two weeks or OTC medicinal products during the last one week preceding the first dosing.
Major illness during 3 months before screening.
Participation in a drug research study within past 3 months.
Donation of blood in the past 3 months before screening.
Female subjects demonstrating a positive pregnancy screen.
Female subjects who are currently breast-feeding.
Female subjects with child bearing potential using prohibited contraceptive method (Oral, Injectable or Implantable hormonal agents).

Study & Design

Arm && Interventions

Group	Intervention	Description
Ropinirole	Ropinirole	Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
Requip	Ropinirole	Requip XL Tablets 2 mg of Glaxosmithkline, USA

Primary Outcome Measures

Name	Time	Method
Area under curve(AUC)	Pre-dose (before dosing, in the morning of the day of dosing) and at 1.00, 2.00, 3.00,4.00, 5.00, 6.00, 7.00, 8.00, 9.00, 10.00, 11.00, 12.00, 13.00, 14.00, 15.00, 16.00, 17.00, 18.00,20.00, 24.00, 30.00, 36.00, 48.00 and 60.00 hours after dosing.

Secondary Outcome Measures

Name	Time	Method

Recruitment & Eligibility